Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Wexner Constipation Score is a structured symptom score used to quantify chronic constipation severity over multiple domains including bowel frequency, evacuation difficulty, incomplete evacuation, assistance needs, and symptom duration.
Formula: Wexner score is the sum of 8 symptom domains, each 0-4 (total range 0-30).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Score 8 parameters over the past month: bowel movement frequency, straining/difficulty with defecation, sensation of incomplete evacuation, abdominal pain with evacuation, time spent per attempt, need for digital assistance or enema, unsuccessful defecation attempts per 24 hours, and duration of constipation symptoms.
Each of the 8 parameters is scored 0–4 based on frequency (0=never, 4=always). Sum all 8 scores for a total ranging from 0–30.
Score 0–8 = normal; 9–14 = mild constipation; 15–20 = moderate constipation; above 20 = severe constipation. Scores above 15 warrant thorough workup including colonic transit studies and anorectal manometry. Scores above 20 may require surgical consultation.
Colorectal surgeons
Quantify constipation severity before surgical interventions (sacral nerve stimulation, colectomy, biofeedback). The Wexner score was developed specifically for colorectal surgery populations and is validated in that clinical context.
Pelvic floor physical therapists
Assess constipation severity in patients with suspected pelvic floor dyssynergia. High Wexner scores combined with difficulty with defecation and incomplete evacuation suggest pelvic outlet obstruction rather than slow-transit constipation.
Surgeons
Document baseline constipation severity before recommending biofeedback therapy. A moderate-to-high Wexner score (15+) with features of pelvic floor dyssynergia supports biofeedback as first-line treatment before surgical options.
Researchers
Use as a validated primary or secondary endpoint in clinical trials for constipation treatments — laxatives, prucalopride, sacral nerve stimulation, or surgical procedures. Wexner score change is a clinically meaningful outcome measure.
Gastroenterologists
Track Wexner score response to osmotic laxatives (PEG 3350), secretagogues (linaclotide, lubiprostone), or prokinetics (prucalopride). Score reduction of 5+ points typically indicates clinically meaningful improvement.
The Wexner Constipation Scoring System was developed and validated by Agachan et al. (1996) specifically for colorectal surgery patients. It is best suited for functional constipation and pelvic outlet obstruction evaluation rather than acute or transient constipation.
A Wexner score above 15 indicates significant constipation that warrants thorough evaluation: colonic transit study (radiopaque markers or scintigraphy), anorectal manometry, and balloon expulsion test. This workup distinguishes slow-transit constipation from pelvic floor dyssynergia — treatments differ substantially.
Rome IV criteria for functional constipation: 2 or more of the following in more than 25% of defecations for at least 6 months: straining, lumpy/hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction, manual maneuvers needed, fewer than 3 spontaneous bowel movements per week. The Wexner score quantifies these same domains.
Pelvic floor dyssynergia (paradoxical puborectalis contraction during defecation straining) is diagnosed by anorectal manometry showing paradoxical sphincter contraction during straining, combined with a failed balloon expulsion test (unable to expel 50mL balloon). This is a common cause of high Wexner scores that does not respond to laxatives alone.
Biofeedback therapy is first-line treatment for pelvic floor dyssynergia with 70–80% response rates (Rao et al., 2007). Patients learn to relax the puborectalis and external anal sphincter during defecation straining. 5–6 sessions are typically required. Biofeedback should be tried before sacral nerve stimulation or surgery.
Polyethylene glycol 3350 (MiraLax, Movicol) is first-line for functional constipation — superior to lactulose in multiple trials (Ford et al., Cochrane 2011). Docusate (stool softener) has weak evidence and is not recommended as monotherapy for chronic constipation. Starting with PEG before escalating to secretagogues is appropriate.
FDA-approved secretagogues for chronic idiopathic constipation: linaclotide (Linzess, 145 mcg daily) and lubiprostone (Amitiza, 24 mcg twice daily). Both increase intestinal fluid secretion and reduce Wexner score. Indicated when PEG fails. Linaclotide is also approved for IBS-C.
Sacral nerve stimulation (neuromodulation) is FDA-approved for refractory chronic constipation. It modulates neural pathways to the colon and pelvic floor. Wexner scores above 20 refractory to medical therapy may warrant SNS evaluation. Success rates of 50–70% in properly selected patients.
Dietary fiber target is 25 g/day for women and 38 g/day for men. Gradual increase prevents gas and bloating — add 5 g/day per week. Both soluble fiber (psyllium, oats — softens stool) and insoluble fiber (wheat bran, vegetables — adds bulk) are beneficial. Adequate fluid intake (8–10 cups/day) is essential to prevent fiber from worsening constipation.
Total colectomy with ileorectal anastomosis is a last-resort surgical option for severe, refractory slow-transit constipation (Wexner scores typically above 20) after all medical and biofeedback treatments have failed and slow transit confirmed by transit studies. Patient selection is critical — pelvic floor dyssynergia must be excluded or treated first.
Wexner Constipation Scoring System published by Agachan et al. (Dis Colon Rectum 1996) from 232 patients at Cleveland Clinic. Internal consistency and face validity established in constipation and fecal incontinence populations. Cutoff 9: distinguishes normal from constipated patients. Validated in multiple colorectal surgery centers internationally. Rome IV criteria for functional constipation: Mearin et al. (Gastroenterology 2016). Biofeedback for pelvic floor dyssynergia: Rao et al. (Am J Gastroenterol 2007) — 70–80% success. PEG 3350 first-line evidence: Ford et al. (Cochrane 2011).
Higher scores represent more severe constipation burden and may support escalation of evaluation/treatment strategy.
Use in chronic constipation assessment, specialist referral baseline documentation, and longitudinal symptom monitoring.
The score is symptom-based and subjective, and should be interpreted with bowel history, medication review, and alarm symptom assessment.
For related assessments, see Bristol Stool Scale, Water Intake and Protein Intake.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Classify stool form using the Bristol Stool Scale to support constipation/diarrhea pattern assessment and symptom tracking.
OpenNutritionCalculate recommended daily water intake based on body weight and activity level, with hydration targets in liters and cups.
OpenNutritionCalculate recommended daily protein intake based on body weight, activity level, and fitness goals.
OpenGastroenterologyCalculate the Rockall score to predict rebleeding and mortality in upper GI hemorrhage. Pre-endoscopy score ≤2: low risk for rebleeding. Post-endoscopy score 0: <5% rebleeding risk.
Open